CN103845342A - Composite drug for treating adolescent polycystic ovarian syndrome (PCOS)-insulin resistance (IR) - Google Patents
Composite drug for treating adolescent polycystic ovarian syndrome (PCOS)-insulin resistance (IR) Download PDFInfo
- Publication number
- CN103845342A CN103845342A CN201210508202.8A CN201210508202A CN103845342A CN 103845342 A CN103845342 A CN 103845342A CN 201210508202 A CN201210508202 A CN 201210508202A CN 103845342 A CN103845342 A CN 103845342A
- Authority
- CN
- China
- Prior art keywords
- pcos
- adolescence
- diane
- treatment
- metformin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a composite drug for treating adolescent PCOS-IR. The drug comprises metformin, Diane-35 and metformin plus Diane-35 and further includes weight reduction through physical adjustment. According to the invention, through combination of weight reduction with metformin, Diane-35 or metformin plus Diane-35, adolescent PCOS-IR is treated, and disease progress can be effectively alleviated and reverse; metabolic characteristics of PCOS-IR are defined, the diagnosis and treatment process of adolescent PCOS-IR is improved, and the composite drug is applicable to diagnosis and treatment of adolescent PCOS-IR.
Description
Technical field
The invention belongs to medicine bioengineering field, relate to a kind of composition of medicine that Polycystic Ovary Syndrome in Adolescence merges insulin resistant for the treatment of.
Background technology
The Therapeutic Method that the research of adolescence PCOS and IR relation and adolescence PCOS merge IR is the focus of the outer research of Present Domestic.Research shows that IR plays an important role in PCOS develops, and the IR of PCOS is mainly relevant with tyrosine phosphorylation deficiency and the serine Hyperphosphorylationof of Insulin receptor INSR, and no matter obese type or non-obese type PCOS all may exist this molecular defect.In adolescence PCOS patient, 25%～35% becomes diabetes and cardiovascular disease to adult development, and this and adolescence PCOS, the especially IR of merging do not obtain medical treatment relevant, and adolescence PCOS merges the high risk factor that IR is considered to adult metabolism syndrome (MS).But because the irregular ovulation of physiological, excessive androgen mass formed by blood stasis, insulin resistant and the Morphological Characteristics of polycystic ovary and the Clinical symptoms of PCOS in Development in Puberty process are quite similar, pathogeny is not clear, often make adolescence PCOS be difficult for finding in time, easily ignore clinically or be difficult for judgement, the diagnosis of adolescence PCOS and treatment are difficult for holding opportunity, cause the delay of diagnosis and treatment.Especially PCOS merges the patient of IR, and its long term complication occurs more early, and incidence rate is higher.Therefore, study its pathogenesis, understanding adolescence PCOS merges the clinical and endocrine metabolism feature of IR, early diagnosis adolescence PCOS and IR, just PCOS intervened and treat in adolescence, correct its endocrine and metabolic disorders, for blocking-up PCOS patient's disease progression, prevention long term complication, improve this crowd quality of life significant.
The treatment that adolescence PCOS is merged to IR still lacks enough experiences and data.Lifestyle change, as motion and reasonable diet, clinical manifestation on adolescence PCOS merging IR and the data of disease progression impact are very limited, but show that loss of weight can reduce fat PCOS patient's plasma testosterone level, increase SHBG, reducing free AI, alleviate insulin resistant, is its near, very effective method of long term complication of prevention.Research is found, improve insulin resistant, the recovery ovary ovulation function of PCOS with the medicine (representing medicine-metformin) that increases insulin sensitivity, be the focus of current PCOS treatment, but apply separately loss of weight or euglycemic agent is all not ideal enough to the improvement of menstruation; Oral contraceptive Diane-35 is a line medication for the treatment of PCOS, not only can compete dihydrotestosterone receptor, suppress 5-alpha-reductase activity, and suppress gonadotrophin secretion and reduce the generation of ovarian androgens, and can directly act on endometrium, stop the excessive pathological changes of endometrial hyperplasia and adjust menstrual cycle.In addition, in oral contraceptive (OCP), estrogenic component (ethinylestradiol) can promote liver sex hormone binding globulin (SHBG), reduces free androgen in circulation.Have the intervention of report life style adolescence PCOS to be merged to the therapeutical effect of IR, the treatment that adolescence PCOS is merged to IR is as few in the report of the scheme comparisons such as loss of weight, application euglycemic agent, oral contraceptive, and the effect of three's therapeutic alliance rarely has report.
Summary of the invention
The object of this invention is to provide a kind of composition of medicine that Polycystic Ovary Syndrome in Adolescence merges insulin resistant for the treatment of, described medicine is made up of metformin, Diane-35 and metformin+Diane-35; Described medicine also comprises that physics adjustment loses weight.
The invention provides a kind of medicine that merges IR for adolescence PCOS, by the comparison that the adjustment of life style physics loses weight, loss of weight associating metformin, loss of weight associating Diane-35, loss of weight associating metformin and four kinds of therapeutic schemes of Diane-35 merge the therapeutic effect of IR to adolescence PCOS, inquire into the mechanism of action of four kinds of therapeutic schemes, provide foundation for exploring therapeutic regimen.Theory and practice basis has been established in the treatment that merges IR for adolescence PCOS.
Therapeutic Method of the present invention can instruct adolescence PCOS treatment clinical course, in diagnostic procedure, increase for the examination of IR, merge in the treatment of IR by use euglycemic agent and fat-reducing effectively to slow down and reverse disease process simultaneously at adolescence PCOS.
The invention has the beneficial effects as follows: clear and definite PCOS merges the metabolic characteristics of IR, improve the diagnosis and treatment process that adolescence PCOS merges IR, be applicable to the diagnoses and treatment that adolescence PCOS merges IR.
The specific embodiment
The present invention is further described in conjunction with specific embodiments.
Embodiment 1
Treatment target is that adolescence PCOS merges IR patient's 40 examples, life style adjustment loses weight, loss of weight associating metformin (0.5g/ days are oral), loss of weight associating Diane-35 (each menstrual cycle first day rise take each 2mg/ days * 21 days oral), loss of weight associating metformin and four kinds of therapeutic schemes of Diane-35, contrast four groups of June after B ultrasonic ovary form improve number of cases and acne improvement situation.
LIF treatment group and matched group follicular development situation are as shown in table 1.
Loss of weight associating metformin and Diane-35 treatment group B ultrasonic ovary form are improved number of cases (P<0.05) and acne and are improved (P<0.05) and be significantly higher than all the other groups (P<0.05), and loss of weight associating metformin and Diane-35 treatment can effectively improve PCOS clinical setting.
Embodiment 2
Treatment target is that adolescence PCOS merges IR patient 20 examples, loss of weight associating metformin and Diane-35 and matched group (nonintervention) two schemes, contrast two groups of June after B ultrasonic ovary form improve number of cases and acne improvement situation.
After loss of weight associating metformin and Diane-35 June, B ultrasonic ovary form is improved number of cases and acne improvement situation is significantly higher than matched group (P<0.05), and loss of weight associating metformin and Diane-35 treatment can effectively improve PCOS clinical setting.
Claims (2)
1. a composition of medicine for the treatment of Polycystic Ovary Syndrome in Adolescence merging insulin resistant, described medicine is made up of metformin, Diane-35 and metformin+Diane-35.
2. a kind of composition of medicine that Polycystic Ovary Syndrome in Adolescence merges insulin resistant for the treatment of according to claim 1, is characterized in that: described medicine also comprises that physics adjustment loses weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210508202.8A CN103845342A (en) | 2012-12-03 | 2012-12-03 | Composite drug for treating adolescent polycystic ovarian syndrome (PCOS)-insulin resistance (IR) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210508202.8A CN103845342A (en) | 2012-12-03 | 2012-12-03 | Composite drug for treating adolescent polycystic ovarian syndrome (PCOS)-insulin resistance (IR) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103845342A true CN103845342A (en) | 2014-06-11 |
Family
ID=50853747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210508202.8A Pending CN103845342A (en) | 2012-12-03 | 2012-12-03 | Composite drug for treating adolescent polycystic ovarian syndrome (PCOS)-insulin resistance (IR) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103845342A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102895456A (en) * | 2011-07-25 | 2013-01-30 | 刘艳萍 | Drug for treating polycystic ovarian syndrome |
-
2012
- 2012-12-03 CN CN201210508202.8A patent/CN103845342A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102895456A (en) * | 2011-07-25 | 2013-01-30 | 刘艳萍 | Drug for treating polycystic ovarian syndrome |
Non-Patent Citations (3)
| Title |
|---|
| 周英惠等: "达英-35联合二甲双胍治疗多囊卵巢综合征临床观察", 《实用中西医结合临床》 * |
| 宋珍等: "二甲双胍联合达英-35治疗青春期多囊卵巢综合征疗效观察", 《中国医疗前沿》 * |
| 魏巍等: "达英-35与胰岛素增敏剂治疗多囊卵巢综合征后促排卵药物的效果观察", 《实用妇产科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blockmans et al. | Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study | |
| BOWER | Pituitary enlargement secondary to untreated primary hypogonadism | |
| Hellmeyer et al. | The use of iv bisphosphonate in pregnancy-associated osteoporosis-case study | |
| CN105596495B (en) | The Chinese medicine compound prescription for treating Polycystic Ovary Syndrome in Adolescence | |
| Brunova et al. | Weight gain in patients after therapy for hyperthyroidism | |
| Yang et al. | Successful pregnancy after improving insulin resistance with the glucagon-like peptide-1 analogue in a woman with polycystic ovary syndrome: a case report and review of the literature | |
| WO2021208280A1 (en) | Application of dried fly larva in preparation of drugs for preventing and treating breast hyperplasia | |
| Demir et al. | Tamoxifen as first-line treatment in a premenarchal girl with juvenile breast hypertrophy | |
| CN103845342A (en) | Composite drug for treating adolescent polycystic ovarian syndrome (PCOS)-insulin resistance (IR) | |
| CN1850244A (en) | Chinese medicine composition for treating eye disease and preparing method | |
| Ushiroyama et al. | Effects of switching to wen-jing-tang (unkei-to) from preceding herbal preparations selected by eight-principle pattern identification on endocrinological status and ovulatory induction in women with polycystic ovary syndrome | |
| Reifenstein Jr et al. | The classic: the metabolic effects of steroid hormones in osteoporosis | |
| Zainudin et al. | A Summary of the Consensus for the Management of Thyroid Disorders in Malaysia | |
| Yonggang et al. | Effects of human chorionic gonadotropin combined with clomiphene on Serum E2, FSH, LH and PRL levels in patients with polycystic ovarian syndrome | |
| CN110755574A (en) | External plaster for treating hyperplasia of mammary glands | |
| Herwana et al. | Soy isoflavone supplementation reduces RANKL/OPG ratio on postmenopausal women with osteopenia | |
| Ellafi | Polycystic Ovarian Syndrome: Evaluating the optimal therap | |
| Semenyna et al. | Modern aspects of treatment of women with polycystic ovary syndrome | |
| Feng et al. | Clinical application of integrated traditional Chinese and Western medicine in the treatment of threatened abortion | |
| Yasar et al. | Effect of misoprostol on bone mineral density in women with postmenopausal osteoporosis | |
| Chu-chu et al. | Clinical efficacy of bushen huatan huoxue recipe in combination with acupuncture in treating patients suffering from polycystic ovary syndrome with insulin resistance. | |
| Wang | Network meta-analysis of exercise intervention in postmenopausal women with osteoporosis | |
| Zhang et al. | Advances in Acupuncture and its Associated Therapies for the Prevention and Treatment of Obesity Type 2 Diabetes Mellitus | |
| CN105169106A (en) | Traditional Chinese medicinal preparation for treating hyperplasia of mammary glands | |
| Liang | How to Utilize Basal Body Temperature (BBT) when Treating Fertility According to Traditional Chinese Medicine (TCM). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140611 |